Bank of New York Mellon Corp boosted its holdings in Intrexon Corp (NYSE:XON) by 3.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 315,438 shares of the biotechnology company’s stock after acquiring an additional 10,691 shares during the period. Bank of New York Mellon Corp’s holdings in Intrexon were worth $2,063,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. lifted its holdings in Intrexon by 4.2% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 45,823 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 1,835 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in Intrexon by 1.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 161,385 shares of the biotechnology company’s stock valued at $1,055,000 after acquiring an additional 2,882 shares during the last quarter. Quantamental Technologies LLC acquired a new position in Intrexon in the fourth quarter valued at approximately $28,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Intrexon by 64.5% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 14,292 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,604 shares during the last quarter. Finally, John G Ullman & Associates Inc. lifted its holdings in Intrexon by 38.7% in the fourth quarter. John G Ullman & Associates Inc. now owns 20,800 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 5,800 shares during the last quarter. Hedge funds and other institutional investors own 84.92% of the company’s stock.
Intrexon stock opened at $4.11 on Monday. Intrexon Corp has a twelve month low of $3.95 and a twelve month high of $19.94.
A number of brokerages have issued reports on XON. Zacks Investment Research raised Intrexon from a “hold” rating to a “strong-buy” rating and set a $8.75 target price on the stock in a research report on Saturday, January 12th. Northland Securities lowered Intrexon from an “outperform” rating to a “market perform” rating in a research report on Friday, March 1st. Finally, JMP Securities reissued a “buy” rating and issued a $43.00 target price on shares of Intrexon in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $34.00.
In other news, major shareholder Randal J. Kirk sold 95,241 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $0.65, for a total transaction of $61,906.65. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Thomas D. Reed sold 225,500 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $4.18, for a total value of $942,590.00. Following the sale, the insider now directly owns 96,280 shares in the company, valued at approximately $402,450.40. The disclosure for this sale can be found here. Insiders have sold 362,419 shares of company stock worth $1,032,421 in the last ninety days. Corporate insiders own 48.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Zolmax and is the property of of Zolmax. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://zolmax.com/investing/intrexon-corp-xon-position-lifted-by-bank-of-new-york-mellon-corp/3053704.html.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Featured Article: What are the economic characteristics of a bear market?
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NYSE:XON).
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.